Yes — relapsed and refractory leukemia is one of the most active areas of leukemia research, and many trials are specifically designed for patients whose disease has come back or stopped responding to prior treatment. For relapsed AML, current studies include menin inhibitors for KMT2A-rearranged or NPM1-mutated disease, second-generation FLT3 and IDH inhibitors, novel bispecific antibodies, and combinations built around venetoclax. For relapsed adult ALL, brexucabtagene autoleucel (Tecartus) is FDA-approved CAR-T therapy, and trials are studying earlier use of CAR-T, next-generation CAR products, and bispecifics like blinatumomab in new combinations. For relapsed CLL, pirtobrutinib (Jaypirca) and other non-covalent BTK inhibitors are in active trials for patients who have progressed on first-generation BTK inhibitors. Comprehensive molecular testing at the time of relapse is essential — many of these trials are mutation-specific, and the right testing can open doors that weren't available before.

In most cases, yes — federal law (the Affordable Care Act, since 2014) requires most health plans to cover the routine medical costs of clinical trials for life-threatening conditions, which includes leukemia. Routine costs include things like office visits, standard lab work, imaging, and hospital stays you would have needed even outside the trial; these are billed to your insurance as they would be in standard care. The trial sponsor typically covers the experimental drug itself and any tests required only for the study (extra biopsies, research-only blood draws, sponsor-required scans). Medicare and Medicaid both cover routine trial costs as well. A few exceptions exist — small-group plans that haven't changed since before 2014 may be grandfathered out, and some plans require pre-authorization — so the safest move is to ask the trial coordinator for a written budget showing what the sponsor covers versus what will be billed to your insurance, and to confirm coverage with your insurer before enrolling.

There are about 673 leukemia trials actively recruiting in the United States today, with the largest share in AML (299), ALL (214), and CLL (165). The right one for you depends on your specific subtype, your genetic and molecular markers (FLT3, IDH1/2, BCR-ABL, TP53, and 17p deletion are the most actionable), what treatments you've already had, and how far you can reasonably travel. ClinicalTrials.gov lists every study but is built for clinicians. North Trials matches you to current leukemia trials based on your diagnosis and location, and your hematologist or the nearest NCI-designated cancer center is also a strong starting point — academic centers typically run more trials than community practices, particularly for AML and acute leukemias where time-to-enrollment can matter clinically.

Clinical trials test new approaches that aren't yet FDA-approved but have shown enough promise in earlier studies to warrant testing in patients. The most common misconception is that "trial" means "experimental and riskier than standard care" — in reality, most leukemia trials either add the new agent to current standard treatment or compare it head-to-head against the best available standard, so you are not being denied established care. Trials also typically include more intensive monitoring than routine treatment: more frequent blood work, more frequent scans or bone marrow assessments, and closer follow-up with the trial team. The trade-off is more clinic time and the possibility of side effects from a drug whose long-term profile is still being characterized. For many patients with leukemia, particularly those with high-risk molecular features or relapsed disease, a trial offers access to therapies that may be the next standard of care months or years before they're widely available.

Eligibility varies trial by trial, but most leukemia studies look at the same core factors: your specific leukemia subtype (AML, ALL, CLL, CML, or rarer types), your age, what prior treatments you've received and how recently, your overall health and performance status, your organ function (blood counts, kidneys, liver, heart), and your tumor's cytogenetic and molecular profile. For acute leukemias in particular, markers like FLT3, IDH1, IDH2, NPM1, and TP53 mutations often determine which targeted-therapy trials you qualify for, and BCR-ABL status is central for CML and some ALL studies. Molecular testing is now standard at diagnosis; if you haven't had it, ask your hematologist about it before searching for trials, because many of the most promising studies are mutation-specific. Not qualifying for one trial doesn't mean none are open to you — a thorough search across multiple sites usually surfaces several options.